Rocket Pharmaceuticals gets FDA fast track status for RP-L401 in infantile malignant osteopetrosis

pharmanewsdaily- August 30, 2020 0

Rocket Pharmaceuticals has secured fast track designation for RP-L401 gene therapy candidate from the US Food and Drug Administration (FDA) for the treatment of infantile ... Read More